**SFA Therapeutics Publications and Presentations**

Feitelson, M. A. (2017) Hepatitis B Virus x Antigen-Associated Hepatocellular Carcinoma. In: Schwab M. (eds) Encyclopedia of Cancer. Springer, Berlin, Heidelberg

McBrearty, N., Arzumanyan, A., Bichenkov, E., Merali, S., Merali, C., and Feitelson, M. A.  Short chain fatty acids delay the development of hepatocellular carcinoma in HBx transgenic mice.  Neoplasia 23:529-538, 2021.

<https://authors.elsevier.com/sd/article/S1476558621000245>

Hurwitz SJ, McBrearty N, Arzumanyan A, Bichenkov E, Tao S, Bassit L, Chen Z, Kohler JJ, Amblard F, Feitelson MA, Schinazi RF. Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator. Viruses 13:114, 2021. <https://doi.org/10.3390/v13010114>

Feitelson, M. A.  Pathogenesis of Hepatitis B Virus Associated Chronic Liver Disease.  In: *Liver Cancer*. Lasfar, A. (ed.).  InTech, Rejika, Croatia, 2018. ISBN: 978-1-78984-448-1 , 978-1-78984-449-8; <https://doi.org/10.5772/intechopen.79746>

Medhat, A., Arzumanyan, A., and Feitelson, M. A.  Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma.  Oncotarget,12(24):2421-2433, 2021.  <https://doi.org/10.18632/oncotarget.28077>

Feitelson, M. A., Arzumanyan, A., Spector, I., and Medhat, A.  Hepatitis B x (HBx) as a component of a functional cure for chronic hepatitis B.  Biomedicines 10:2210-27, 2022.  Special issue of Biomedicines on  "Hepatitis B virus infection: From cell entry to carcinogenesis. Understanding viral replication, cell pathogenesis, disease, and treatments."  Villanueva, R. (ed).  <https://doi.org/10.3390/biomedicines10092210>

Feitelson, M., and Arzumanyan, A. (eds.). Liver Cancer: Genesis, Progression and Metastasis. Intech Open 2023. Online ISBN: 978-1-80356-414-2. Print ISBN: 978-1-80356-414-5.

Feitelson, M. A. and Arzumanyan, A. (eds.). Emanuel E. Canfora, E. E., Feitelson, M. A., and Arzumanyan, A. Editorial: Microbiome Metabolites in Health and Disease. In: Frontiers in Microbiology, 14:1270001, 2023. <https://doi.org/10.3389/fmicb.2023.1270001>

Feitelson, M. A., Arzumanyan, A, Medhat, A., and Spector, I.  The Role of Short Chain fatty Acids in Cancer Pathogenesis.  In: Cancer and Metastasis Reviews.  Special Issue: Functional Molecules-based Approaches in Cancer Therapeutics.  Fiering, S., Kaushik,  A., Gupta, V. K. (eds.). 2023.  <https://doi.org/10.1007/s10555-023-10117-y>

Zhang N, Wang F, Yang X, Wang Q, Chang R, Zhu L, Feitelson MA, Chen Z. TMEM43 promotes the development of hepatocellular carcinoma by activating VDAC1 through USP7 deubiquitination. Translational Gastroenterology and Hepatology 9:9, January 25, 2024. doi: 10.21037/tgh-23-108. PMID: 38317750.

Roy, S. S., Naghdi, S., Mishra, P., Weaver, D., Walter, L., Davies, E., Antony, A. N., Lin, X., Moehren, G., Feitelson, M. A., Reed, C. A., Lindsten, T., Thompson, C. B., Hoek, J. B.,Knudsen, E. S.,and Hajnóczky, G. Mitochondrial apoptosis mediated through VDAC2 and Bak is upregulated in hepatocarcinoma, providing an Achilles’ heel for therapy. Nature Communications, accepted for publication.

Feitelson, M. A. The Enigma of Hepatitis B Therapeutics. In: Hepatitis B Virus - Pathogenesis and Therapeutic Approaches. Feitelson, M. A. (ed.). InTech, Rejika, Croatia, 2024, ISBN 978-0-85466-578-5, in press.

**Presentations:**

Kolabtree Blog: SFA Therapeutics listed among “The 10 Most Promising Biotech Startups in the United States” on June 15, 2018.

Philadelphia Inquirer: “Stellar Start-ups” published September 9, 2018; Awards presented at the Bowl, Beer and Cheer event, SouthBowl, Philadelphia, September 13, 2018. SFA Therapeutics was among the finalists and received a recognition award for outstanding achievement and promise.

BIO Start-up stadium finalist (within the top 40 global biotech start-up companies), Boston, MA, June 4-7, 2018

SFA Therapeutics has been selected as one of 10 global finalists in the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology; GlobeNewswire – New York, NY – February 27, 2019.

SFA Therapeutics interviewed by Proactive/GoodDay Bio in October 2019.

Press release: SFA Therapeutics Announces FDA Approval to Begin IND Trial for Mild to Moderate Psoriasis. Cision PR Newswire, June 29, 2020.

SFA Therapeutics was recognized as as one of the top innovative startup companies by a panel of investors from BioHouston and the Rice Alliance for Technology and Entrepreneurship on November 16, 2020.

SFA Therapeutics won the Therapeutics & Enabling Technologies Track Company Presentation Award for the SFA presentation at BioNJ’s Eleventh BioPartnering Conference co-sponsored by J.P. Morgan and Johnson & Johnson Innovation, May 20, 2021.

SFA Therapeutics selected for the Y-Combinator resource training program. June 7, 2021.

International Research Awards on Oncology and Cancer Research Award Winner, Best research Presentation, Sponsored by Pencis for presentation at a Webinar on October 4, 2021.

SFA named among the Most Fundable Companies at Pepperdine Graziadio Business School, September 9, 2021 (Gold category).

<https://www.entrepreneur.com/slideshow/397785>

<https://www.businesswire.com/news/home/20211014006084/en/Pepperdine-Graziadio-Business-School-Announces-the-2021-List-of-Most-Fundable-Companies>

SFA Therapeutics won First Place in the National Venture Plan Competition by Pismo Ventures (Nov. 5, 2021) [Pismo Ventures' National Venture Plan Startup Competition Announces Winners (prweb.com)](https://www.prweb.com/releases/2022/1/prweb18419468.htm)

Three Rivers Venture Fair Finalist in 2021.

Profiled in Entrepreneur Magazine, December, 2021.

Press release: SFA closes Seed Round at $4M. EINPRESSWIRE [https://www.einpresswire.com/article/576955468/sfa-therapeutics-inc-closes-seed-round-raise-of-4m](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.einpresswire.com%2Farticle%2F576955468%2Fsfa-therapeutics-inc-closes-seed-round-raise-of-4m&data=05%7C01%7Cmark.feitelson%40temple.edu%7Ce76d892e1a8f46df9f7f08da52d71edb%7C716e81efb52244738e3110bd02ccf6e5%7C0%7C0%7C637913381140794397%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=9F2l9HTifwQh0ewoG85QnncAJ3aynrjwcaL8s6Mls9Q%3D&reserved=0)

Press release: [https://www.einpresswire.com/article/591853533/sfa-therapeutics-publishes-research-on-its-new-approach-to-treating-hepatitis-b-and-chronic-liver-disease](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.einpresswire.com%2Farticle%2F591853533%2Fsfa-therapeutics-publishes-research-on-its-new-approach-to-treating-hepatitis-b-and-chronic-liver-disease&data=05%7C01%7Cmark.feitelson%40temple.edu%7C6c755daef804483fc62908da9d8b051f%7C716e81efb52244738e3110bd02ccf6e5%7C0%7C0%7C637995517713390709%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=icFfra7L3XlaCgefJ03KsssKjDsgA8JIeo6gZ1xAPHI%3D&reserved=0)

*Wall Street Journal with Brian Gormley -*[*Tales From the 2022 Biotech VC Fundraising Trail*](https://www.wsj.com/articles/tales-from-the-2022-biotech-vc-fundraising-trail-11671667063) December 22, 2022

*Philadelphia Business Journal* with John George - [A little company with a big vision': Temple spinout advancing new way to treat autoimmune disorders](https://www.bizjournals.com/philadelphia/news/2023/01/04/sfa-therapeutics-jenkintown-temple-metabolites.html) January 4, 2023

*BioBuzz* with Mark Terry- SFA Therapeutics Has Big Vision to Transform Medicine. January 10, 2023.

PharmaVoice interview with Ira Spector. January 26, 2023. <https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.pharmavoice.com%2Fnews%2Fbiotech-ceo-Ira-Spector-SFA-Therapeutics-psoriasis%2F641369%2F&data=05%7C01%7Cmark.feitelson%40temple.edu%7Cd410388b6e144565aacc08db0084f8b3%7C716e81efb52244738e3110bd02ccf6e5%7C0%7C0%7C638104343488479093%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C2000%7C%7C%7C&sdata=I0yUt447DsY6vb%2FisL9qjDIJ%2Bkae4IjMAQyxX8J8Ks8%3D&reserved=0>

* Podcast interview with Ira Spector. Applied Clinical Trials Magazine. “Treat Disease. Not the Symptoms.” March 7, 2023 [https://www.appliedclinicaltrialsonline.com/view/treat-disease-not-the-symptoms](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.appliedclinicaltrialsonline.com%2Fview%2Ftreat-disease-not-the-symptoms&data=05%7C01%7Cmark.feitelson%40temple.edu%7C3c9f6d2ba87b473b80e408db1f3d6492%7C716e81efb52244738e3110bd02ccf6e5%7C0%7C0%7C638138120763527888%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=N%2BPUkHfimAUsrpTy4phSX7glVPAk0Rf4muxFpKwwsoU%3D&reserved=0)
* May 6 interview with Ed Silverman of ***STAT***, resulting in the May 10 article: [Up and down the ladder: The latest comings and goings](https://www.statnews.com/pharmalot/2024/05/10/jobs-ladder-pfizer-sanofi-novartis-sfa-gilead/).
* Mention in the May 3 ***Fierce Biotech*** [Chutes and Ladders](https://www.fiercebiotech.com/biotech/chutes-ladders-bridgebio-oncology-execs-take-reins-new-spinout) article.
* May 3 ***The Dermatology Digest*** article: [Dr. Stefan C. Weiss Joins SFA Therapeutics as Chief Medical Officer](https://thedermdigest.com/dr-stefan-c-weiss-joins-sfa-therapeutics-as-chief-medical-officer/).
* May 3 ***The Pharma Letter*** article: [SFA Therapeutics names CMO to strengthen management team](https://www.thepharmaletter.com/article/sfa-therapeutics-names-cmo-to-strengthen-management-team)
* May 4 ***My ChesCo*** article: [SFA Therapeutics Appoints Esteemed Dermatologist Stefan C. Weiss as Chief Medical Officer](https://www.mychesco.com/a/news/regional/sfa-therapeutics-appoints-esteemed-dermatologist-stefan-c-weiss-as-chief-medical-officer/).
* Feitelson, M. A., Arzumanyan, A. and Spector, I. The Promise of Therapeutics from Molecules within Our Body. Drug Target Review, Russell Publishing, 16 May 2024.

[https://www.drugtargetreview.com/article/148867/the-promise-of-therapeutics-from-](https://www.drugtargetreview.com/article/148867/the-promise-of-therapeutics-from-       molecules-within-our-body/)

[molecules-within-our-body/](https://www.drugtargetreview.com/article/148867/the-promise-of-therapeutics-from-       molecules-within-our-body/)

* Mention in the May 31 ***MedCity News*** – [Healthcare Moves: A Monthly Summary of Hires and Layoffs](https://medcitynews.com/2024/05/healthcare-executive-hire-layoffs-2/) article.
* Mention in theJune 2024 ***Nature Biotech*** [People](https://www.nature.com/articles/s41587-024-02278-0) feature.
* ***Progress, Potential, and Possibilities*** podcast, published on April 8: [Dr. Ira Spector, PhD - CEO, Co-Founder, SFA Therapeutics - Microbiome Derived Immunomodulating Drugs](https://www.youtube.com/watch?v=1zaxSyLVqNo).
* ***My ChesCo*** article highlighting the Phase 1b enrollment completion: [SFA Therapeutics Completes Key Phase 1b Trial Enrollment for Psoriasis Treatment](https://www.mychesco.com/a/news/regional/sfa-therapeutics-completes-key-phase-1b-trial-enrollment-for-psoriasis-treatment/).
* ***Dermatology Times***, published on June 20: [SFA-002 Shows Promise in Early Clinical Trial Psoriasis Cohorts](https://www.dermatologytimes.com/view/sfa-002-shows-promise-in-early-clinical-trial-psoriasis-cohorts).
* ***The Pharma Letter***’s [Ones to Watch](https://www.thepharmaletter.com/ones-to-watch/sfa-therapeutics).
* SFA Therapeutics presented at the BioLabs Investor Day on April 27, 2023 in the Curtis Center (BIO International Convention, Boston, MA)
* Press Release: SFA Therapeutics announces results for SFA-002 from Phase 1b Cohort 1 clinical trial for treatment of mild-to-moderate psoriasis.

<https://www.globenewswire.com/news-release/2023/08/14/2724489/0/en/SFA-Therapeutics-announces-results-for-SFA-002-from-Phase-1b-Cohort-1-clinical-trial-for-treatment-of-mild-to-moderate-psoriasis.html>

* Abstract presentations: McBrearty, N., Arzumanyan, A., and Feitelson, M.A. Short chain fatty acids (SCFAs) delay the progression of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC).
* Invited Speaker: BIT’s 11th Annual World Cancer Congress, Philadelphia Marriott Downtown. May 18-20, 2018.
* Presented at the 2019 Keystone Symposia Conference on Epigenetics and Human Disease Fairmont in Banff Springs, Banff, Alberta on March 17 - March 21, 2019.
* 4th DRUG DISCOVERY Leadership NEXUS (DDN) which took place in Boston, Massachusetts on 16th and 17th of May, 2019.
* Presented SFA at Taiwan Forum: Global Biotech Entrepreneurship. Innovation beyond borders. Held at Temple University, June 2, 2019.
* Invited talk: SFA technology was presented at the 7th Microbiome R&D & Business Collaboration Forum, 29th-30th October 2019, San Diego, CA
* Presented at the HepDart meeting, Grand Hyatt Hotel, Kauai, Hawaii on December 8-12, 2019.
* Virtual conference: 5th Drug Discovery Strategic Summit 2020, held on May 14, 2020, sponsored by the Agile Falcon Strategic Group.
* Virtual Conference: Keynote speech: Cell Science Webinar, November 18-20, 2020. Oral presentation: Short chain fatty acids (SCFAs) delay the progression of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). Sponsored by Confrontiers. <https://www.confrontiers.com/cellscience-conference-virtual-2020/agenda>
* Virtual Conference: 4th Annual Digital NASH Summit 2020. December 15-18, 2020. Oral presentation: Short chain fatty acids (SCFAs) delay the progression of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC).Sponsored by Hansonwade, London, England.
* Presented as an e-poster at the Canadian Liver Meeting 2021 (virtual) on May 2-5, 2021. .
* Invited Speaker: 2nd International Conference on Hepatitis, June 14, 2021 | webinar https://hepatitis.conferenceseries.com/europe/
* Invited Speaker: Short Chain Fatty Acids Delay the Pathogenesis of Hepatitis B Virus-Associated Hepatocellular Carcinoma in an HBx Transgenic Mouse Model. 19th Annual Congress of International Drug Discovery Science and Technology (IDDST), May 11-13, 2022, Tokyo, Japan
* Presented at the Innovation Nest Grand Opening, Temple University Dental School, March 19, 2024.
* Invited Speaker: “HBV and hepatocellular carcinoma: novel therapeutic targets.” Presented at the Fox Chase Cancer Center, April 1, 2016.
* Invited Speaker: “Symbiotic bacteria provide chemoprevention against hepatitis B virus mediated hepatocellular carcinoma in HBx transgenic mice.”
* Presented at the Second International Conference on Hepatology, held at the Doubletree Hilton Hotel, Skokie, Ill, May 9-11, 2016.
* Presented at the International Conference on Cancer Research and Targeted Therapy, held at the Holiday Inn, Inner Harbor, Baltimore, MD., October 21-23, 2016.
* Presented at the International Pharmaceutical Conference and Expo, Doubletree Hilton Hotel, Philadelphia International Airport, March 21-23, 2018.
* Virtual Conference: 5th International Conference on Gastroenterology and Hepatology" which was held during November 23-24, 2020. Oral presentation on: “Selected Probiotic Bacteria and Short Chain Fatty Acids Delay the Pathogenesis of Hepatitis B Virus-Associated Hepatocellular Carcinoma.” Sponsored by Allied Academics
* Signing of the SFA Therapeutics-Temple University License Agreement on Friday, August 11, 2017, at 1pm, at Conwell Hall, in Conference Room 404.
* Invite: Temple University Innovation Gala, November 15, 2017, at the Kimmel Center’s Rooftop Hamilton Garden, 300 S Broad St, Philadelphia, PA (recognition and honoring innovation at Temple).
* Pre-Investigational New Drug Application (PIND) file for SFA-AC1002. Submitted March 14, 2018. FDA response April 26, 2018 granting permission to proceed with Phase II human clinical trials for adults with plaque psoriasis.
* SFA Therapeutics named one of the 20 amazing companies to meet by Angel Venture Fair, June 28, 2018.
* Participant: Nestlé Skin Health Shield, Skin Microbiome Summit, 430 E. 29th Street, 11th Floor, NY, NY., March 6, 2019.
* SFA Therapeutics selected by Lyfebulb and Helsinn among 10 Finalists for the 2019 Innovation Summit in Oncology. GlobeNewswire – New York, NY – February 27, 2019.
* Presented SFA to Dr. Joel Gelfand, head of Dermatology at the University of Pennsylvania, about clinical trials in psoriasis patients under his care. May 24, 2019.
* SFA Therapeutics filed for an Orphan Drug Designation (ODD) with the FDA for SFA001 to treat hepatocellular carcinoma, on Friday, July 26, 2019. Designation received 10/22/19.
* Organizing Committee Member to our "International Conferences and Exhibitions on Pharmaceutics & Novel Drug Delivery systems,” held on September 09-10, 2019 in Osaka, Japan.
* Invited to present SFA at Endless Frontier Labs starting September 2019 graduating from the program in May 2020. Start-up company accelerator at Tisch Hall in NYU’s Stern School of Business.
  + Presented at NYC MedTech program in partnership with the American Technion Society, SUNY Global Center, NY, NY. March 5, 2020.
* SFA Therapeutics, Inc has been selected as one of Hello Tomorrow’s Deep Tech Pioneers and invited to present at the Business and Investor Days on March 10-11th, 2020 and at the Global Summit on March 12-13th, 2020 in Paris, France (was virtual).
* Symposium panelist: Sponsored by the Joseph Priestley Society at the Science History Institute: “Can you trust your gut? Using the microbiome to cure disease.” Moderated by Dr. Maria L. Maccecchini at the Science History Institute on February 13, 2020.
* Wilson Sonsini Goodrich & Rosati took over IP representation and invested in SFA Therapeutics ($50,000 in kind and 1% of the company).
* FDA approved an experimental IND in psoriasis for SFA002. A Phase 1b clinical trial started in mild-moderate psoriasis or SFA002. The Phase 2A protocol was approved by the FDA for SFA002. A preIND plan was filed with FDA and accepted for SFA002. Spring, 2020.
* Letter of endorsement for SFA from Ground Zero Pharmaceuticals (Aug. 2, 2021). Letter of endorsement from C3 Research Associates (July 27, 2021)
* Letter of endorsement from Seyfarth showing patents on numerous natural products (July 29, 2021)
* Invited Speaker: Short chain fatty acids as drugs against chronic inflammatory diseases. Center for Microbiology and Immunology, Temple University School of Medicine, September 13, 2021. Invited by Dr. Cagle Tukel.
* Invited Speaker: The human microbiome as a source of drugs for chronic inflammatory diseases of aging.
* 8th Annual Congress of the European Society for Translational Medicine (EUSTM-2021) 20-26 September 2021 (Virtual Congress).
* European Society of Medicine's annual congress (ESMED Congress 2021), November 11-13, 2021, Hotel Mercure Wien City, Vienna, Austria (Oncology workshop)
* Presented at Drug Discovery Virtual Nexus East Coast 2022. April 21, 2022.
* 7th International Conference on Cancer Research and Drug Development, October 24-26, 2022, Lord Baltimore Hotel, Baltimore, MD.
* MDPI World Hepatitis Day Webinar held on July 28, 2023.
* Drug Screening and Pharmacology Summit, virtual presentation sponsored by [www.scientificcrew.com/drug-screening/](http://www.scientificcrew.com/drug-screening/) on September 18-20, 2023.
* Presented virtually at the 4th Symposium on World Cancer Research (SWCR-2024). April 22-25, 2024 at the Intercontinental Hotel, Singapore. <https://swcr2024.lmsii.org/agenda>
* Presented virtually at the International Conference on Microbiology & Infectious Diseases. May 13-14, 2024, Paris, France. Microbiology Conferences in 2024 Infectious Diseases Event (stripeconferences.com)
* Presented at: Precision in Drug Discovery and Preclinical Summit. Sponsored by Precision Evolution Global, Boston, MA held at the Hilton Boston Park Plaza on June 10-11, 2024. https://events.precision-globe.com/register/39